Document:

exv10w1

Exhibit 10.1

[ANALOG DEVICES LETTERHEAD]

November 18, 2008

David Zinsner

8125 Regency Dr.

Pleasanton, CA 94588

Dear David,

It is a great pleasure to offer you employment to join Analog Devices as Vice President and Chief
Financial Officer, reporting to Jerry Fishman.

You will be paid at the bi-weekly rate of $17,307.69 which is annualized at $450,000.00.

In addition, you are eligible to participate in our semi annual Bonus Program based on goals that
are set annually by the Company. The bonus target for your position is 75% of your base
compensation. You are also eligible for an additional Individual Payout Factor. This factor can
increase the calculated bonus payment by up to 30% based on superior business performance as
recommended by the CEO and approved by the Compensation Committee. Evidence of superior business
performance will include, but is not limited to, overachievement of revenue and profitability goals
and achievement of non-financial results that contributed positively to the performance of the
company. Eligibility for the Bonus Program begins during your first full fiscal quarter of
employment with ADI.

In order to assist you with relocation and in addition to the benefit of our relocation policy, you
will be eligible for a grossed-up award of the difference between: (i) the average of two
appraisals of the value of your home in Pleasanton, CA (assuming the home was marketed for six
months), and (ii) the actual selling price of your home, capped at a maximum of $100,000
(grossed-up), provided you sell your home before September 1, 2009. This relocation benefit expires
on September 1, 2009.

The Compensation Committee of the Board of Directors has approved a nonqualified stock option grant
of 160,000 shares under the terms of the Analog Devices, Inc., 2006 Stock Incentive Plan.
The “grant date” of this recommended option grant will be the 15th of the month following your
start date or the next trading day of the NYSE, as applicable. The grant price of this option grant
will be based on the closing ADI stock price on the “grant date”. Shares granted under this option
will become eligible for exercise in annual installments of one-fifth per year of the total shares
granted, beginning one year from the “grant date”. You will receive further information regarding
this grant after your start date.

The Compensation Committee of the Board of Directors has also approved a restricted stock unit
award (RSU) for 35,000 shares under the terms of the Analog Devices, Inc. 2006 Stock
incentive Plan. The “grant date” of this recommended RSU award will be the 15th day of the month
following the month in which you were hired or the next trading day of the NYSE, as applicable.
Subject to the terms of the RSU award, each one (1) RSU shall, upon vesting, automatically convert
into one (1) share of Common Stock of Analog Devices. This RSU award will vest in annual
installments of one-fifth per year of the total RSU awarded, beginning one year from the “grant
date”. You will also receive further information regarding this award, including important tax
information, after your start date.

In addition, as an exception to our policy, Analog Devices agrees to a vacation accrual rate of 4
weeks per year.

You should be aware that your employment relationship with Analog Devices will be on an “at will”
basis. This means that either you or ADI may terminate the employment relationship at any time, for
any reason, or without a reason, and without prior notice. In the event that ADI terminates your
employment other than for cause or unsatisfactory performance, you will receive a severance payment
in accordance with the standard provisions of the ADI severance plan.

You will be provided with the enclosed Employee Retention Agreement in which provides that, in the
event a Change of Control occurs, you will be paid in the amount equal to the sum of (A) 299% of
the higher of (i) your annual base salary in effect at the time of the Termination (as defined in
the agreement) or (ii) your annual base salary in effect immediately prior to the Change of
Control, plus (B) 299% of the aggregate cash bonuses paid or awarded to you in respect of the four
fiscal quarters preceding the Date of Termination. Please review the enclosed Employee Retention
Agreement for more details.

 

 

You will be eligible for the Company’s Deferred Compensation Program. Please review the enclosed
Deferred Compensation Program Plan for further details.

Employment with Analog Devices provides you with the opportunity to participate in various employee
benefit programs including group health, life, and disability insurance; a tuition assistance
program; and, a retirement savings plan with a generous Company contribution beginning upon
completion of a year of service. Benefits information can be viewed in more detail on our corporate
web site.

Our offer of employment is contingent upon verification of employment information provided in your
employment process, successful completion of a background check, proof of employment eligibility,
and signing of our Employment Agreement. Jeanne Mancuso, our HR Assistant for Corporate (781-461-
3372), can answer any questions you might have regarding these verifications.

Two copies of this offer letter are provided. Please confirm your acceptance of our offer by
signing in the space provided. Return one copy in the enclosed envelope; the other copy is for your
files.

Also enclosed with this letter are several forms and info sheets that you will need to read and/or
fill out and send back with your confirmed acceptance of our offer.

Dave, we believe you will be an excellent addition to the Analog Devices team and look forward to
your starting with us. We are certain you will find your employment with Analog Devices both
challenging and rewarding.

If you have any questions or concerns, please do not hesitate to contact me at (781) 461-3148.

Sincerely,

/s/ William Matson

William Matson

Vice President, Human Resources

	 	 	 
	I accept the above offer and will tentatively begin my employment on:

	 	 
	 

	 	 

	 	 	 	 	 	 	 
	Signature

	 	/s/ David A. Zinsner
	 	Date:exv4w1

AMENDED AND RESTATED

INVESTOR RIGHTS AGREEMENT

     This Amended and Restated Investor Rights Agreement (the “Agreement”) is made as of
the 12th day of February, 2009 (the “Effective Date”), by and among Xata
Corporation, a Minnesota corporation (the “Company”) and each of those persons and entities,
severally and not jointly, listed on the Schedule of Investors attached as Exhibit A hereto (each,
an “Investor” and collectively, the “Investors”).

     This Agreement amends and restates in its entirety the Investor Rights Agreements, dated as of
June 19, 2007, by and among the parties hereto.

     Reference is made to the Common Stock Warrant and Series E Preferred Stock Purchase Agreement
(the “Series E Purchase Agreement”), and the Exchange Agreement (the “Exchange Agreement”), each
dated as of the date hereof, and each by and among the Company and the Investors, and certain other
parties listed on the respective signature pages thereto.

AGREEMENT

     In consideration of the mutual covenants contained in this Agreement, and for other good and
valuable consideration, the receipt of which is hereby acknowledged, the Company and each Investor
(severally and not jointly) hereby agree as follows:

SECTION 1. Definitions. Capitalized terms used and not otherwise defined herein that are
defined in the Series E Purchase Agreement shall have the meanings given such terms in the Series E
Purchase Agreement. As used in this Agreement, the following terms shall have the following
meanings:

	 	 	“Affiliate” means, with respect to any specified Person, any other Person who, directly or
indirectly, controls, is controlled by, or is under common control with such Person,
including without limitation any general partner, managing member, officer or director of
such Person or any investment fund now or hereafter existing that is controlled by one or
more general partners or managing members of, or shares the same management company with,
such Person.
	 
	 	 	“Investor Shares” means the shares of Series B Preferred Stock, Series C Preferred Stock,
Series D Preferred Stock, Series E Preferred Stock, Series F Preferred Stock and/or Common
Stock of the Company held by the Investors or their Affiliates on any given date (calculated
on an as-converted to Common Stock basis). Attached hereto as Exhibit B is a list of the
Investor Shares that will be outstanding immediately following the Initial Closing.
	 
	 	 	“Person” means any individual, corporation, partnership, trust, limited liability company,
association or other entity.
	 
	 	 	“Series B Purchase Agreement” means the Common Stock Warrant and Series B Preferred Stock
Purchase Agreement, dated December 6, 2003, by and among the Company and the Investors.

1

 

	 	 	“Series C Purchase Agreement” means the Common Stock Warrant and Series C Preferred Stock
Purchase Agreement, dated September 7, 2005, by and among the Company and the Investors.
	 
	 	 	“Series D Purchase Agreement” means the Common Stock Warrant and Series D Preferred Stock
Purchase Agreement, dated June 19, 2007, by and among the Company and the Investors.
	 
	 	 	“Series F Preferred Stock” means the shares of Preferred Stock of the Company to be issued
pursuant to the Exchange Agreement.
	 
	 	 	"Trident Capital” means Trident Capital, Inc.

SECTION 2. Right of First Refusal

     2.1 Subsequent Offerings. Each Investor shall have a right of first refusal to purchase its
pro rata share of all Equity Securities, as defined below, that the Company may, from time to time,
propose to sell and issue after the date of this Agreement, other than the Equity Securities
excluded by Section 2.4 hereof. Each Investor’s pro rata share is equal to the ratio of (a) the
number of shares of the Company’s Common Stock (including all shares of Common Stock issuable upon
conversion of the Preferred Stock or exercise of any outstanding warrants or options) of which such
Investor is deemed to be a holder immediately prior to the issuance of such Equity Securities to
(b) the total number of shares of the Company’s outstanding Common Stock (including all shares of
Common Stock issuable upon conversion of the Preferred Stock or exercise of any outstanding
warrants or options) immediately prior to the issuance of the Equity Securities. The term “Equity
Securities” shall mean (i) any Common Stock, Preferred Stock or other security of the Company, (ii)
any security convertible into or exercisable or exchangeable for, with or without consideration,
any Common Stock, Preferred Stock or other security (including any option to purchase such a
convertible security), (iii) any security carrying any warrant or right to subscribe to or purchase
any Common Stock, Preferred Stock or other security or (iv) any such warrant or right.

     2.2 Exercise of Rights. If the Company proposes to issue any Equity Securities in a public
offering or a private placement, the Company shall give each Investor written notice of its
intention, describing the Equity Securities, the price and the terms and conditions upon which the
Company proposes to issue the same. Each Investor shall have 20 days from the giving of such
notice to agree to purchase its pro rata share of the Equity Securities for the price and upon the
terms and conditions specified in the notice by giving written notice to the Company and stating
therein the quantity of Equity Securities to be purchased. Such exercise of rights may be made
contingent upon a minimum number of shares being purchased in such transaction.

     2.3 Transfer of Rights of First Refusal. The rights of first refusal of each Investor under
this Section 2 may be transferred to the same parties, subject to the same restrictions as any
transfer of registration rights pursuant to Section 9.7 of the Series E Purchase Agreement.
Without limiting the foregoing, upon receipt from the Company of the notice called for by Section
2.2, the Investors shall be entitled to apportion among themselves and their Affiliates, in such
proportions as they deem appropriate, the rights of first refusal granted to them by this

2

 

Section 2 with respect to the proposed issuance covered by such notice; provided,
however, that a right of first refusal under this Section 2 may not be apportioned to any
Person that is not an institutional accredited investor and the Investors must comply with all
federal and state securities laws in making such apportionment.

     2.4 Excluded Securities. The rights of first refusal established by this Section 2 shall have
no application to any of the following Equity Securities:

          (a) shares of Common Stock and/or options, warrants or other Common Stock purchase rights and
the Common Stock issued pursuant to such options, warrants or other rights issued or to be issued
after the date of execution of this Agreement to employees, officers or directors of, or
consultants or advisors to the Company or any subsidiary, pursuant to stock purchase or stock
option plans or other arrangements that are approved by the Board of Directors;

          (b) stock issued or issuable pursuant to any rights or agreements, options, warrants or
convertible securities outstanding as of the date of this Agreement;

          (c) any Equity Securities issued for consideration other than cash pursuant to a merger,
consolidation, acquisition or similar business combination;

          (d) any Equity Securities issued in connection with any stock split, stock dividend or
recapitalization by the Company; and

          (e) any Equity Securities issued by the Company pursuant to the terms of the Series E Purchase
Agreement or the Exchange Agreement (including, without limitation, any Equity Securities issued
upon exercise, exchange or conversion of any such Equity Securities).

     2.5 Termination of Rights of First Refusal. The rights of first refusal of the Investors
under this Section 2 shall terminate on the date the total number of Investor Shares comprises less
than 25% of the total number of Investor Shares as of immediately following the Closing.

SECTION 3. Special Voting Rights

     3.1 Special Voting Rights. For so long as the total number of Investor Shares comprises at
least 30% of the total number of Investor Shares held by the Investors as of immediately following
the Closing, the Company shall not, without first obtaining the approval of holders of a majority
in interest of the Investor Shares on such date:

          (a) enter into a transaction with an affiliated or interested party except upon terms not less
favorable to the Company than it could obtain in a comparable arm’s length transaction with an
unaffiliated or disinterested third party;

          (b) create (by new authorization, reclassification, recapitalization, designation or
otherwise) or issue any class or series of stock or any other securities convertible into equity
securities of the Company having any right, preference or privilege senior to or on parity with

3

 

any series of preferred stock of the Company then held by any Investor with respect to voting,
dividends, redemption or liquidation preference;

          (c) alter or change the rights, preferences or privileges of the shares of Series B Preferred
Stock, Series C Preferred Stock, Series D Preferred Stock, Series E Preferred Stock or Series F
Preferred Stock (whether by merger, recapitalization or otherwise) so as to affect adversely such
shares, or increase the authorized number of shares of any such series of Preferred Stock;

          (d) enter into any bankruptcy filing, liquidation, assignment for the benefit of creditors or
similar event of the Company or any significant subsidiary;

          (e) make any redemption, repurchase, payment or declaration of any dividend or distribution on
any shares of capital stock of the Company other than the Series B Preferred Stock, Series C
Preferred Stock, Series D Preferred Stock Series E Preferred Stock or Series F Preferred Stock; or

          (f) issue or sell, or be deemed to have issued or sold, Common Stock for an Effective Price
(as defined below) less than the then-current Fair Market Value (as defined below) of the Company’s
Common Stock.

               (i) For the purposes of this section (f), the “Fair Market Value” of the Company’s Common
Stock shall mean:

                    (A) If the Company’s Common Stock is traded on a securities exchange (which shall include the
Nasdaq Stock Market), the value shall be deemed to be the average of the closing prices of the
Common Stock on such exchange over the 30 day period ending on the date prior to the closing of the
sale and issuance of the shares of Common Stock;

                    (B) If Corporation’s Common Stock is traded over-the-counter, the value shall be deemed to be
the average of the closing bid or sale prices (whichever are applicable) over the 30 day period
ending on the date prior to the closing of the sale and issuance of the Equity Securities; and

                    (C) If there is no public market for the Company’s Common Stock, the value shall be the fair
market value thereof, as determined in good faith by the Board of Directors of the Company.

               (ii) For the purposes of this section (f), if the Company issues or sells (x) Preferred Stock
or other stock, options, warrants, purchase rights or other securities convertible into shares of
Common Stock (such convertible stock or securities being herein referred to as “Convertible
Securities”) or (y) rights or options for the purchase of Common Stock or Convertible Securities
and if the Effective Price (as defined below) of such shares of Common Stock is less than the
then-current Fair Market Value, in each case the Company shall be deemed to have issued at the time
of the issuance of such rights or options or Convertible Securities the maximum number of shares of
Common Stock issuable upon exercise or conversion thereof and to have received as consideration for
the issuance of such shares an

4

 

amount equal to the total amount of the consideration, if any, received by the Company for the
issuance of such rights or options or Convertible Securities.

               (iii) For the purposes of this paragraph (f) the “Effective Price” of the Common Stock shall
mean the quotient determined by dividing the total number of shares of Common Stock issued or sold,
or deemed to have been issued or sold by the Company under this paragraph (f), into the Aggregate
Consideration received, or deemed to have been received by the Company for such issue under this
section, for such shares of Common Stock. In the event that the number of shares of Common Stock
or the Effective Price cannot be ascertained at the time of issuance, such shares of Common Stock
shall be deemed to have an Effective Price below the then-current Fair Market Value. The
“Aggregate Consideration” received by the Company for any issue or sale of securities shall be
defined as: (A) to the extent it consists of cash, be computed at the gross amount of cash received
by the Company before deduction of any underwriting or similar commissions, compensation or
concessions paid or allowed by the Company in connection with such issue or sale and without
deduction of any expenses payable by the Company, (B) to the extent it consists of property other
than cash, be computed at the fair value of that property as determined in good faith by the Board,
and (C) if shares of Common Stock, Convertible Securities (as defined below) or rights or options
to purchase either shares of Common Stock or Convertible Securities are issued or sold together
with other stock or securities or other assets of the Company for a consideration which covers
both, be computed as the portion of the consideration so received that may be reasonably determined
in good faith by the Board to be allocable to such shares of Common Stock, Convertible Securities
or rights or options.

               (iv) The provisions of section (f) shall not apply to issuances of:

                    (A) shares of Common Stock issued upon conversion of the Series B Preferred Stock, Series C
Preferred Stock, Series D Preferred Stock, Series E Preferred Stock or Series F Preferred Stock, or
exercise of the warrants issued in connection with the original issuance of Series B Preferred
Stock, Series C Preferred Stock, Series D Preferred Stock or Series E Preferred Stock;

                    (B) shares of Common Stock or Convertible Securities issued to employees, officers or
directors of, or consultants or advisors to the Company or any subsidiary pursuant to stock
purchase or stock option plans or other arrangements that are approved by the Board provided that,
(i) such options were granted with an exercise price equal to or greater than the then-current fair
market value (as “fair market value” is defined in the relevant plan) or (ii) such shares were
issued pursuant to a IRC 423 plan with an exercise price equal to or greater than 85% of the
then-current fair market value (as such “fair market value” is defined in the relevant plan);

                    (C) shares of Common Stock issued pursuant to the exercise of Convertible Securities
outstanding as of the date of filing of the Certificate of Designation for the Series E Preferred
Stock (including without limitation the Series B Preferred Stock, Series C Preferred Stock, Series
D Preferred Stock and Series E Preferred Stock);

5

 

                    (D) shares of Common Stock or Convertible Securities issued for consideration other than cash
pursuant to a merger, consolidation, acquisition, strategic alliance or similar business
combination approved by the Board; and

                    (E) shares of Series F Preferred Stock issued pursuant to the Exchange Agreement.

SECTION 4. Company Covenants

     4.1 Termination and Election of President or Chief Executive Officer. Prior to any
termination of the employment of the Company’s President and/or Chief Executive Officer or any
selection of a new President and/or Chief Executive Officer, the Company agrees to consult, in good
faith, with Trident Capital on matters relating to such termination or the selection of the
Company’s next President and/or Chief Executive Officer.

     4.2 Director and Officer Insurance. The Company shall maintain in full force and effect
director and officer liability insurance in the amount of $5,000,000, or such other amount as the
Board of Directors determines to be appropriate in light of relevant facts and circumstances,
provided however, that, for so long as the total number of Investor Shares comprises at least 25%
of the total number of Investor Shares as of immediately following the Closing, (i) the amount of
such insurance coverage shall not be changed to an amount less than $3,000,000 unless Trident
Capital approves such change, and (ii) the Company shall notify Trident Capital at least 30 days in
advance of any termination of such insurance coverage.

SECTION 5. Information Rights

     5.1 Basic Financial Information and Reporting. For so long as the total number of Investor
Shares comprises at least 25% of the total number of Investor Shares as of immediately following
the Closing:

          (a) As soon as practicable after the end of each fiscal year of the Company, and in any event
within 90 days thereafter, the Company will furnish to Trident Capital a copy of its Annual Report
on Form 10-K, or if such report is not available, a balance sheet of the Company, as at the end of
such fiscal year, and a statement of income and a statement of cash flows of the Company, for such
year, prepared in accordance with generally accepted accounting principles consistently applied
(except as noted therein) and setting forth in each case in comparative form the figures for the
previous fiscal year, all in reasonable detail. Such financial statements shall be accompanied by
a report and opinion thereon by independent public accountants of national standing selected by the
Company’s Board of Directors.

          (b) The Company will furnish to Trident Capital, as soon as practicable after the end of the
first, second and third quarterly accounting periods in each fiscal year of the Company, and in any
event within 45 days thereafter, a copy of its Quarterly Report on Form 10-Q, or if such report is
not available, a balance sheet of the Company as of the end of each such quarterly period, and a
statement of income and a statement of cash flows of the Company for such period and for the
current fiscal year to date, prepared in accordance with generally accepted accounting principles
consistently applied (except as noted therein), with the exception

6

 

that no notes need be attached to such statements and year-end audit adjustments may not have
been made.

          (c) The Company will furnish to Trident Capital: (i) at least 30 days prior to the beginning
of each fiscal year an annual budget, business plans for such fiscal year (and as soon as
available, any subsequent updates thereto in the event of any material changes to such budget,
business plan or financial forecast); and (ii) as soon as practicable after the end of each month,
and in any event within 30 days thereafter, a balance sheet of the Company as of the end of each
such month, and a statement of income and a statement of cash flows of the Company for such month
and for the current fiscal year to date, including a comparison to plan figures for such period,
prepared in accordance with generally accepted accounting principles consistently applied (except
as noted thereon), with the exception that no notes need be attached to such statements and
year-end audit adjustments may not have been made.

     5.2 Inspection Rights. For so long as the total number of Investor Shares comprises at least
25% of the total number of Investor Shares as of immediately following the Closing, Trident Capital
shall have the right to visit and inspect any of the properties of the Company or any of its
subsidiaries, and to discuss the affairs, finances and accounts of the Company or any of its
subsidiaries with its officers, and to review such information as is reasonably requested all at
such reasonable times and as often as may be reasonably requested.

SECTION 6. Amendments to Series B and Series C Purchase Agreements

     6.1 Each of Sections 10.1, 10.2, 10.3, 10.4, 10.5, 11.1, 12.1, 12.2, 12.3, 12.4, 13.1, and
13.2 of the Series B Purchase Agreement is hereby amended and restated in its entirety to read as
follows: “Intentionally Omitted.”

     6.2 Each of Sections 10.1, 10.2, 10.3, 10.4, 10.5, 11.1, 12.1, 12.2, 12.3, 12.4, 13.1, and
13.2 of the Series C Purchase Agreement is hereby amended and restated in its entirety to read as
follows: “Intentionally Omitted.”

     SECTION 7. Notices. All notices required in connection with this Agreement shall be in
writing and shall be deemed effectively given upon the earlier of actual receipt of: (a) personal
delivery to the party to be notified, (b) one business day after the date of confirmed transmission
by facsimile, (c) five days after having been sent by registered or certified mail, return receipt
requested, postage prepaid, or (d) one business day after the business day of deposit with a
nationally recognized overnight courier, specifying next day delivery, freight prepaid, with
written notification of receipt, and addressed as follows:

          (a) if to the Company, to:

XATA Corporation

965 Prairie Center Drive

Eden Prairie, MN 55344

Attention: Chief Financial Officer

Facsimile: 952-641-5848

Email: mark.ties@xata.com

7

 

with a copy to:

Faegre & Benson LLP

2200 Wells Fargo Center

Minneapolis, MN 55402

Attention: Michael Coddington

Facsimile: (612) 766-1600

Email: mcoddington@faegre.com

               or to such other person at such other place as the Company shall designate to the
Investors in writing; and

          (b) if to Trident Capital, to:

Trident Capital, Inc.

505 Hamilton Avenue, Suite 200

Palo Alto, CA 94304

Attn: Howard S. Zeprun

Chief Administrative Officer and General Counsel

with a copy to:

Mark Tanoury, Esq.

Cooley Godward Kronish LLP

Five Palo Alto Square

3000 El Camino Real

Palo Alto, CA 94306-2155

          (c) if to an Investor, at the address as set forth below such Investor’s name on the Schedule
of Investors, or at such other address or addresses as may have been furnished to the Company in
writing, with a copy to:

Mark Tanoury, Esq.

Cooley Godward Kronish LLP

Five Palo Alto Square

3000 El Camino Real

Palo Alto, CA 94306-2155

SECTION 8. Miscellaneous

     8.1 Waivers and Amendments. Neither this Agreement nor any provision hereof may be changed,
waived, discharged, terminated, modified or amended except upon the written consent of the Company
and holders of at least a majority of the shares of Series B Preferred Stock, Series C Preferred
Stock, Series D Preferred Stock, Series E Preferred Stock and Series F Preferred Stock then held by
the Investors (including any shares of Common Stock issued upon conversion of such shares and then
held by the Investors).

8

 

     8.2 Headings. The headings of the various sections of this Agreement have been inserted for
convenience of reference only and shall not be deemed to be part of this Agreement.

     8.3 Severability. In case any provision contained in this Agreement should be invalid,
illegal or unenforceable in any respect, the validity, legality and enforceability of the remaining
provisions contained herein shall not in any way be affected or impaired thereby.

     8.4 Governing Law. This Agreement shall be governed by and construed in accordance with the
corporate laws of the State of Minnesota and, with respect to matters of law other than corporate
law, the laws of the State of Minnesota as applied to contracts entered into and performed entirely
in Minnesota by Minnesota residents, without regard to conflicts of law principles.

     8.5 Counterparts. This Agreement may be executed in two or more counterparts, each of which
shall constitute an original, but all of which, when taken together, shall constitute but one
instrument, and shall become effective when one or more counterparts have been signed by each party
hereto and delivered to the other parties.

     8.6 Successors and Assigns. Except as otherwise expressly provided herein, the provisions
hereof shall inure to the benefit of, and be binding upon, the successors, assigns, heirs,
executors and administrators of the parties hereto.

     8.7 Entire Agreement. This Agreement and other documents delivered pursuant hereto, including
the exhibits, constitute the full and entire understanding and agreement between the parties with
regard to the subjects hereof and thereof.

9

 

     8.8 Fees and Expenses. If any action at law or in equity is necessary to enforce or interpret
the terms of this Agreement, the prevailing party shall be entitled to reasonable attorney’s fees,
costs and necessary disbursements in addition to any other relief to which such party may be
entitled.

     8.9 Confidentiality. Each Investor covenants that it will maintain in confidence the receipt
and content of any notice, or request for consent, waiver or approval, received thereby pursuant to
the terms of this Agreement or the registration rights provisions of any of the Series B Purchase
Agreement, Series C Purchase Agreement, Series D Purchase Agreement or Series E Purchase Agreement,
until such information (a) becomes generally publicly available other than through a violation of
this provision by any Investor or its agents or (b) is required to be disclosed in legal
proceedings (such as by deposition, interrogatory, request for documents, subpoena, civil
investigation demand, filing with any governmental authority or similar process); provided,
however, that before making any disclosure in reliance on this Section 8.9, the Investor will give
the Company at least 15 days prior written notice (or such shorter period as required by law)
specifying the circumstances giving rise thereto and the Investor will furnish only that portion of
the non-public information which is legally required and will exercise its best efforts to ensure
that confidential treatment will be accorded any non-public information so furnished; provided,
further, that notwithstanding each Investor’s agreement to keep such information confidential, each
Investor makes no such acknowledgement that any such information is material, non-public
information.

[Signature page follows]

10

 

     In Witness Whereof, the parties hereto have caused this Agreement to be executed by
their duly authorized representatives as of the day and year first above written.

COMPANY:

XATA CORPORATION

	 	 	 	 	 
	 	 
	 	By:  	 	 
	 	 	Wesley C. Fredenburg 	 
	 	 	General Counsel 	 
	 

INVESTORS:

Trident Capital Fund-V, L.P.

Trident Capital Fund-V Affiliates Fund, L.P.

Trident Capital Fund-V Affiliates Fund (Q), L.P.

Trident Capital Fund-V Principals Fund, L.P.

Trident Capital Parallel Fund-V, C.V.

Executed on behalf of the forgoing funds by the undersigned, as an authorized signatory of the
respective general partner of each such fund:

	 	 	 
	 

	 	 
	 
	 	 
	(signature)
	 	 
	 
	 	 
	 
	 	 
	(print name)
	 	 

[Amended and Restated Investor Rights Agreement]

 

EXHIBIT A

SCHEDULE OF INVESTORS

Trident Capital Fund-V, L.P.

505 Hamilton Avenue

Suite 200

Palo Alto, CA 94301

Attn: Howard S. Zeprun

          Chief Administrative Officer and General Counsel

Trident Capital Fund-V Affiliates Fund, L.P.

505 Hamilton Avenue

Suite 200

Palo Alto, CA 94301

Attn: Howard S. Zeprun

          Chief Administrative Officer and General Counsel

Trident Capital Fund-V Affiliates Fund (Q), L.P.

505 Hamilton Avenue

Suite 200

Palo Alto, CA 94301

Attn: Howard S. Zeprun

          Chief Administrative Officer and General Counsel

Trident Capital Fund-V Principals Fund, L.P.

505 Hamilton Avenue

Suite 200

Palo Alto, CA 94301

Attn: Howard S. Zeprun

          Chief Administrative Officer and General Counsel

Trident Capital Parallel Fund-V, C.V.

505 Hamilton Avenue

Suite 200

Palo Alto, CA 94301

Attn: Howard S. Zeprun

          Chief Administrative Officer and General Counsel

 

EXHIBIT B

SCHEDULE OF INVESTOR SHARES

	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Holder	 	Common Shares	 	Series B Shares	 	Series C Shares	 	Series D Shares	 	Series E Shares
	Trident Capital
	 	 	0	 	 	 	1,759,808	 	 	 	1,136,849	 	 	 	1,403,400	 	 	 	907,942	 
	Fund-V, L.P.
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Trident Capital
	 	 	0	 	 	 	10,227	 	 	 	6,607	 	 	 	8,156	 	 	 	5,277	 
	Fund-V Affiliates
Fund, L.P.
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Trident Capital
	 	 	0	 	 	 	9,760	 	 	 	6,305	 	 	 	7,783	 	 	 	5,036	 
	Fund-V Affiliates
Fund (Q), L.P.
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Trident Capital
	 	 	0	 	 	 	50,936	 	 	 	32,905	 	 	 	40,620	 	 	 	26,279	 
	Fund-V Principals
Fund, L.P.
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Trident Capital
	 	 	0	 	 	 	133,698	 	 	 	86,370	 	 	 	106,621	 	 	 	68,980	 
	Parallel Fund-V,
C.V.
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 

13

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00153-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00153-of-00352.parquet"}]]